Magstim announced that the FDA cleared its next-generation Horizon Inspire system for delivering transcranial magnetic stimulation (TMS). Clearance paves the way for the use of the TMS technology to treat patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD) and anxious depression.
Minneapolis-based Magstim designed Horizon Inspire to address physician needs with high-power air cooling and the ability to deliver back-to-back customizable treatments. It offers ease of use, cost-effectiveness and portability between clinic rooms.
Related: Momentis Surgical wins FDA nod for second-gen surgical robot
The company built Horizon Inspire on its Magstim TMS technology, which has prior FDA clearances. It leverages intuitive preset clinical workflows to simplify the treatment process. Magstim says its system delivers precise results with no pulse decay, ensuring the correct dosage. The air-cooled coil reduces downtime and eliminates additional cooling expenses, while advanced data analytics tools improve treatment efficacy.
“Physicians, nurse practitioners and mental health care professionals tell us that patients are searching for alternatives to pharmaceutical treatments,” said Ronnie Stolec-Campo, CEO, Magstim. “FDA cleared transcranial magnetic stimulation is a proven and effective treatment with minimal side effects. We designed the Inspire to enable both experienced TMS providers as well as those who are new to TMS.”
“Magstim engineered the very first commercially available TMS research technology, and we remain committed to our foundation of research. We are unique in the industry because we do not charge pay per use fees, we maintain a dedicated service and support team, and we manufacture our own technology.”
